MedTrace Logo

The Effects of AMPC in the Treatments of Refractory or Relapsed AML

NCT03825146 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-02-24

No results posted yet for this study

Summary

A private trial for evaluating the overall response rate contributed by AMPC in AML in refractory or relapsed AML

Conditions

  • Acute Myeloid Leukaemia Recurrent

Interventions

BIOLOGICAL

Autologous Multi-lineage Potential Cells (AMPC)

Multi-lineage potential cells which were induced to de-differentiate from somatic leukocytes from peripheral blood. Cells are autologous with respect to the patient, and are prepared in a suspension and administered via intravenous infusion. An estimated average of 1 x 10\^8 (0.5 to 5.0 x 10\^8) cells/per suspension(275 to 450mL) will be infused into the patient via intravenous infusion on day 5. Cell counts depend on yield of initial leukocyte harvest on day 0.

Sponsors & Collaborators

  • Lai Corporation Pty. Ltd.

    lead INDUSTRY

Principal Investigators

  • Supachai Ekwattanakit, Ph.D, M.D. · Panacee Hospital Rama 2

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-04
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03825146 on ClinicalTrials.gov